Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

pembrolizumab 3lenvatinib 2Specimen Handling 2Nivolumab 2Cisplatin 2trastuzumab deruxtecan 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1aldesleukin 1Therapeutic Touch 1Surveys and Questionnaires 1Respiratory Function Tests 1Radiotherapy 1Radiation 1Prochlorperazine 1Positron-Emission Tomography 1Platinum 1Paclitaxel 1Ondansetron 1O(6)-codeine methyl ether 1Nelfinavir 1Meperidine 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Loperamide 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Atropine × 90 days × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡